54.70

2.76% 1.705

Rhythm Pharmaceuticals Inc (RYTM)

Overview News Price History Option Chain Financials Discussions Forecast

Rhythm Pharmaceuticals Inc stock is traded at $54.70, with a volume of 353.00K. It is up +2.76% in the last 24 hours and up +9.72% over the past month. Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Previous Close:

$52.99

Open:

$53.24

24h Volume:

353.00K

Relative Volume:

1.02

Market Cap:

$3.24B

Revenue:

$91.93M

Net Income/Loss:

$-273.87M

P/E Ratio:

-16.68

EPS:

-3.28

Net Cash Flow:

$-140.47M

1W Performance:

+9.92%

1M Performance:

+9.72%

6M Performance:

+24.44%

1Y Performance:

+101.90%

1-Day Range:

$52.46

$54.88

1-Week Range:

$47.61

$54.88

52-Week Range:

$23.83

$55.64

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name

Rhythm Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

857-264-4280

Address

222 BERKELEY STREET, BOSTON, MA

Employee

226

Twitter

@rhythmpharma

Next Earnings Date

2024-11-05

Latest SEC Filings

RYTM's Discussions on Twitter

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-08-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy
Jan-18-23	Resumed	Canaccord Genuity	Buy
Aug-08-22	Upgrade	Goldman	Neutral → Buy
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-22	Reiterated	Needham	Buy
Mar-02-22	Resumed	Stifel	Buy
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-14-21	Resumed	Goldman	Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral
Jan-08-20	Initiated	Goldman	Sell
Jul-12-19	Upgrade	Stifel	Hold → Buy
Jul-08-19	Initiated	Canaccord Genuity	Buy
Mar-13-19	Initiated	Ladenburg Thalmann	Buy
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy
Jun-15-18	Reiterated	Needham	Buy
Oct-30-17	Initiated	BofA/Merrill	Buy
Oct-30-17	Initiated	Needham	Buy

View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

Nov 04, 2024

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 7.4%Here's Why - MarketBeat

Nov 04, 2024

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 - The Manila Times

Nov 04, 2024

Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024 - Marketscreener.com

Nov 04, 2024

What's Next: Rhythm Pharmaceuticals's Earnings Preview - Benzinga

Nov 04, 2024

(RYTM) Investment Analysis - Stock Traders Daily

Nov 04, 2024

Nov 03, 2024

Assenagon Asset Management S.A. Decreases Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Nov 03, 2024

Nov 02, 2024

Nisa Investment Advisors LLC Has $3.47 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Nov 02, 2024

Oct 30, 2024

Needham & Company LLC Reaffirms Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat

Oct 30, 2024

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 30, 2024

Oct 29, 2024